Being an ADVOCATE for People with ANCA Vasculitis

Clin J Am Soc Nephrol. 2021 Oct;16(10):1581-1583. doi: 10.2215/CJN.03670321. Epub 2021 Jun 3.

Authors

Hans-Joachim Anders¹, Daigo Nakazawa²

Affiliations

¹ Renal Division, Department of Medicine IV, University Hospital of the Ludwig Maximilian University, Munich, Germany.
² Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.

No abstract available

Keywords: ANCA; complement; glomerulonephritis; vasculitis.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aniline Compounds / adverse effects
Aniline Compounds / therapeutic use*
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / diagnosis
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / drug therapy*
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / immunology
Complement Activation / drug effects*
Complement Inactivating Agents / adverse effects
Complement Inactivating Agents / therapeutic use*
Drug Therapy, Combination
Equivalence Trials as Topic
Humans
Immunosuppressive Agents / adverse effects
Immunosuppressive Agents / therapeutic use*
Nipecotic Acids / adverse effects
Nipecotic Acids / therapeutic use*
Receptor, Anaphylatoxin C5a / antagonists & inhibitors*
Research Design
Treatment Outcome

Substances

Aniline Compounds
C5AR1 protein, human
Complement Inactivating Agents
Immunosuppressive Agents
Nipecotic Acids
Receptor, Anaphylatoxin C5a
avacopan